News and Trends 19 Apr 2023
Forbion raises €1.35B to invest in life science companies
European life sciences venture capital firm Forbion has raised €1.35 billion ($1.5 billion) for its two newest funds, bringing the…
Forbion Capital Partners
- Latest Posts
Opinion 28 Feb 2023
Life changing treatments for rare disease – a beacon of hope
By Sander Slootweg, managing partner, Forbion More than 300 million people around the globe are affected by a rare disease.…
News and Trends 17 Jun 2022
Beyond Biotech podcast 1: Forbion, OMass, PharNext
It's the first official Beyond Biotech podcast! And this week, we have three interviews. We talked with Ros Deegan, CEO…
News and Trends 9 Jun 2022
New Forbion life sciences fund hits €470M
European life sciences venture capital firm Forbion, has announced the first €470M ($500M) close of its Forbion Growth Opportunities Fund…
ADVERTISEMENT
News and Trends 15 Mar 2022
Biotech Stocks in “Total Eclipse” as Financial Pressures Mount
More than a year after biotech stock indices peaked, the markets are worse than ever. Meanwhile, rumors of an impending…
News and Trends 10 Dec 2021
European Biotech Investors Cap Off Record Year in Fundraising
The year 2021 is closing with a biotech investment rush as Eir Ventures, Apollo Health Ventures, and Merck’s venture capital…
News and Trends 13 Jul 2020
Forbion Raises €185M to Fuel Late-Stage European Biotechs
The Dutch life sciences venture capital firm Forbion has bagged €185M in the first closing of a fund aimed at…
More News! 19 Nov 2018
Anti-Inflammatory Treatments Get €40M Boost in Series B
A Series B funding round has whipped up €40M for the Irish company Inflazome. This money will help to fund…
News and Trends 1 Oct 2018
Update: Forbion’s Life Science Fund Tops Goal by €90M
Update: The European venture capital firm Forbion closed fundraising for it's fourth life sciences fund at €360M, a much greater…
News and Trends 12 Apr 2018
British Biotech Raises £29M Round to Fight Lung Disease
Enterprise Therapeutics has raised a substantial Series B financing round to bring its treatments for respiratory diseases into clinical development.…
News and Trends 12 Dec 2017
New Dutch Biotech Sails Straight into Phase II with €25M Series A to Treat NASH
NorthSea Therapeutics has been founded in the Netherlands to develop a drug against NASH, a disease with no treatment and…
Interview 20 Jun 2017
“We’re at a second revolution in cancer therapy” – Experts discuss the Future of Oncology at Refresh
A panel of experts in immuno-oncology discussed the challenges and opportunities to develop therapies that can effectively fight cancer. "I think…
Interview 8 May 2017
Meet the co-developer of the first commercial mAb and gene therapy
Sander van Deventer is now a managing partner at Forbion after playing a critical role in the development of the…
News and Trends 28 Mar 2017
Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?
Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor of “The First Gene Therapy”…
News and Trends 7 Feb 2017
Swiss Parkinson’s Biotech raises Massive €29M in Series B from Top European VCs
Top European VCs have invested €29M in Prexton Therapeutics to support two Phase II trials of its lead candidate foliglurax…
In Depth 7 Feb 2017
Not to be Underestimated: What’s the Hype around NASH?
Since 2014, investment in Non-Alcoholic SteatoHepatitis (NASH) has taken off with a fervor reminiscent of immuno-oncology. What’s it all about?…
ADVERTISEMENT
News and Trends 26 Dec 2016
The Largest Deals, Fundraising and Exits of 2016 in European Biotech
Curious about which technologies have attracted the most cash in biotech finance this year? Here's a list of the most impressive cash…
News and Trends 13 Apr 2016
Leading Biotech VC in Europe Raises over €180M
Forbion has raised €183M for its 3rd capital fund - a big win for this top-notch Dutch VC, especially when…
Best in Biotech 12 Apr 2016
18 of the Best European VCs for Biotech in 2016
As Genentech is celebrating its 40th Birthday, it is also the 40th birthday of Biotechnology and the 40th birthday of…
News and Trends 1 Mar 2016
Here’s why this leading EU Investor turned to NASH
Akarna Therapeutics (US & UK) just raised $15M (€13M) in a series B round led by Forbion Partners - one of…
